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Cynthia M. Fehres1, Astrid J. van Beelen1, Sven C.M. Bruijns1, Martino Ambrosini1, Hakan Kalay1,
Louis van Bloois2, Wendy W.J. Unger1, Juan J. Garcia-Vallejo1, Gert Storm2,3, Tanja D. de Gruijl4 and
Yvette van Kooyk1
CD14+ dendritic cells (DCs) present in the dermis of human skin represent a large subset of dermal DCs (dDCs)
that are considered macrophage-like cells with poor antigen (cross)-presenting capacity and limited migratory
potential to the lymph nodes. CD14+ dDC highly express DC-speciﬁc ICAM-3-grabbing non-integrin (DC-SIGN),
a receptor containing potent endocytic capacity, facilitating intracellular routing of antigens to major
histocompatibility complex I and II (MHC-I andII) loading compartments for the presentation to antigen-speciﬁc
CD8+ and CD4+ T cells. Here we show using a human skin explant model that the in situ targeting of antigens to
DC-SIGN using glycan-modiﬁed liposomes enhances the antigen-presenting capacity of CD14+ dDCs.
Intradermal vaccination of liposomes modiﬁed with the DC-SIGN-targeting glycan LewisX, containing melanoma
antigens (MART-1 or Gp100), accumulated in CD14+ dDCs and resulted in enhanced Gp100- or MART-1-speciﬁc
CD8+ T-cell responses. Simultaneous intradermal injection of the cytokines GM-CSF and IL-4 as adjuvant
enhanced the migration of the skin DCs and increased the expression of DC-SIGN on the CD14+ and CD1a+
dDCs. These data demonstrate that human CD14+ dDCs exhibit potent cross-presenting capacity when targeted
in situ through DC-SIGN.
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INTRODUCTION
Dendritic cells (DCs) have the ability to capture, process, and
present antigens within the context of major histocompat-
ibility complex I and II (MHC-I and-II) to CD8+ and CD4+ T
lymphocytes, respectively, thereby initiating and maintaining
adaptive immune responses (Steinman and Banchereau,
2007). DCs can present exogenous-derived antigens on
MHC-I in a process known as cross-presentation. This
phenomenon holds great interest, as it can directly contribute
to the induction of antitumor CD8+ T-cell responses.
Preferred strategies for DC targeting as cancer immunother-
apy are based on the delivery of tumor antigens to DCs
in vivo. This requires modiﬁcation of antigens to allow
recognition by speciﬁc DCs resulting in antigen internaliza-
tion. Promising targets are the C-type lectin receptors (CLRs),
which are expressed by distinct DCs and are known to
internalize the antigen and to induce T-cell responses, such as
DEC-205 (Hawiger et al., 2001; Bonifaz et al., 2002;
Boscardin et al., 2006) and DC-speciﬁc ICAM-3-grabbing
non-integrin (DC-SIGN) (Singh et al., 2009; Unger et al.,
2012). Most studies use monoclonal antibodies to target DC
subsets (Hawiger et al., 2001; Bonifaz et al., 2002; Sancho
et al., 2008; Idoyaga et al., 2011; Schreibelt et al., 2012).
However, antibodies can induce adverse immunogenic
effects that obstruct the induction of successful antitumor
responses (Chari, 2008). Using natural glycan ligands for CLRs
would be a more versatile approach, as glycans are expressed
throughout the body and therefore they are poorly
immunogenic. DEC-205 has shown to be a potent lectin to
internalize antigens and to induce antigen-speciﬁc T-cell
responses after antigen targeting using DEC-205-speciﬁc
antibodies (Idoyaga et al., 2011). However, still no natural
glycan ligands are described to bind to DEC-205 (Shrimpton
et al., 2009). Therefore, we excluded DEC-205 from analyses
in this study.
It has been demonstrated that the modiﬁcation of antigens
using DC-SIGN-binding glycans resulted in efﬁcient
antigen internalization and increased T-cell responses
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(Wang et al., 2007; Aarnoudse et al., 2008; Singh et al., 2009;
Unger et al., 2012), making DC-SIGN an attractive receptor
for targeting. Ligands for DC-SIGN comprise high-mannose
oligosaccharides and Lewis-type epitopes, such as LewisX
(LeX) (Appelmelk et al., 2003). DC-SIGN is highly expressed
on in vitro–generated monocyte-derived DCs (moDCs), on
DCs at mucosal sites, as well as in skin and lymph nodes
(Engering et al., 2004). The main populations of DCs that can
be found in the human skin are the CD1ahighLangerin+
Langerhans cells (LCs) present in the epidermis, the CD1a+/
CD1c+ DC subset present in the dermis, and the CD14+
dermal DCs (dDCs) (Klechevsky et al., 2008; Klechevsky
et al., 2009; Segura et al., 2012). In humans, DC-SIGN is
primarily expressed by CD14+ dDCs. LCs were shown to
efﬁciently prime CD8+ T cells, whereas CD14+ dDCs induced
the generation of follicular T-helper cells (Klechevsky et al.,
2008). CD1c+ dDCs have recently been described as the
functional equivalents of mouse CD11b+ DCs and possess
Th17-polarizing capacities (Schlitzer et al., 2013). In addition,
it has been shown that human CD1a+ dDCs stimulated CD4+
T-cell proliferation and primed CD8+ T cells (Santegoets et al.,
2008). Whether in situ DC-SIGN targeting inﬂuences the
T-cell priming capacities of the skin DC subsets is currently
not known.
Here, we used glycan-modiﬁed liposomes to target DC-
SIGN+ DCs intradermally to induce tumor-speciﬁc T-cell
responses. Liposomes are spherical nanoparticles, which
can encapsulate large quantities of molecules, such as anti-
tumor peptides. The human skin model resembles the physio-
logical in vivo situation, allowing the examination of targeting
speciﬁcity of vaccine formulation to DC subsets within the skin
tissue, as well as the potential to alter the cross-presenting
capacity of skin DC subsets to induce tumor-speciﬁc T-cell
responses.
RESULTS
LeX- and αDC-SIGN-modiﬁed liposomes are internalized
by DC-SIGN
As previously reported, LeX can bind with high afﬁnity to
DC-SIGN (Appelmelk et al., 2003). We conjugated LeX to
liposomes to target DC-SIGN+ DCs. As a positive control, we
also modiﬁed liposomes with anti-DC-SIGN antibodies (αDC-
SIGN). Indeed, DC-SIGN-Fc constructs bound to the LeX and
αDC-SIGN liposomes coated to ELISA plates (Figure 1a).
Modiﬁcation of liposomes with LeX or αDC-SIGN resulted in
enhanced binding to DC-SIGN and an increased internaliza-
tion of modiﬁed liposomes by monocyte-derived dendritic
cells (moDCs), as measured by an increase in the mean
ﬂuorescent intensity (MFI) (Figure 1b and Supplementary
Figure S2 online). When cultured at 37 °C, all liposomes are
internalized and are located inside the DCs (Supplementary
Figure S2 online). Both the percentage of DiD+ DCs and the
MFI increased upon modiﬁcation of the liposomes with LeX
glycans or αDC-SIGN antibodies (Supplementary Figure S1
online). LeX-and αDC-SIGN-modiﬁed liposomes were equally
well internalized by DC-SIGN+ moDCs, indicating that
glycans are as efﬁcient to target DC-SIGN as antibodies.
Besides DC-SIGN, moDCs do express other CLRs, such as the
mannose receptor, Dendritic Cell ImmunoReceptor, and
Macrophage Galactose-type Lectin (MGL) (Figure 1c). To
exclude that these CLRs contributed to the liposomal
internalization, we incubated moDCs with LeX-modiﬁed
liposomes in the presence of neutralizing mAbs against
mannose receptor, MGL, DCIR, and langerin. As shown in
Figure 1d, internalization of LeX- and αDC-SIGN-modiﬁed
liposomes was solely mediated through DC-SIGN, as the
addition of neutralizing antibodies directed against the other
CLRs did not hamper liposomal internalization. Neutralizing
antibodies against DC-SIGN completely abrogated the inter-
nalization of Lex-modiﬁed liposomes (Figure 1d).
DC-SIGN is mainly expressed by CD14+ dDCs
We analyzed DC-SIGN expression on the three main
migratory DC subsets present in the human skin. As shown
in Figure 2, DC-SIGN is mainly expressed by the CD14+
dDCs. Moderate expression of DC-SIGN was found on the
CD1a+ dDCs, whereas human LCs do not express DC-SIGN
(Figure 2).
Intradermal injection of GM-CSF and IL-4 mobilizes and
matures skin DCs
We investigated the potential of intradermally injected
Toll-like receptor (TLR) ligands to mobilize and mature
skin DCs, as these characteristics inﬂuence T-cell activation.
We tested a panel of TLR ligands (the TLR3 ligand pI:C;
the TLR4 ligand LPS and the TLR7/8 ligand R848) in the
skin and analyzed the subset distribution and maturation
state of emigrated CD14+ and CD1a+ dDCs. We also injected
GM-CSF and IL-4 (GM/4), as administration of GM/4 has
been shown to enhance migration of the phenotypically
more mature CD1a+ dDCs (de Gruijl et al., 2006; Fehres
et al., 2014). Indeed, injection of GM/4 resulted in
higher levels of migrated HLA-DR+ DCs as compared with
injection of medium or the TLR ligands (Figure 3a). Further-
more, GM/4 signiﬁcantly reduced the percentage of
migrated CD14+ DCs from 33 to 8%, whereas the percentage
of migrated CD1a+ dDCs increased from 43 to 75%
(Figure 3b). The TLR ligands did not affect the ratio of
CD14+/CD1a+ dDCs. Although GM/4 reduced the percen-
tage of CD14+ dDCs, absolute numbers of migrated CD14+
dDCs were unaffected by GM/4 administration compared
with medium (Figure 3c, right panel). Rather, the decreased
percentage of CD14+ dDCs was caused by an increase in
the absolute numbers of migrated CD1a+ dDCs (Figure 3c,
left panel).
Besides, intradermal injection of GM/4 increased the
expression of DC-SIGN by CD14+ and CD1a+ dDCs, which
was not observed upon injection of TLR ligands (Figure 3d
and e). GM-CSF, in the absence of IL-4, was found to be the
main factor responsible for the upregulation of DC-SIGN
during in vitro moDC generation (Conti et al., 2008).
To determine whether the upregulation of DC-SIGN on
skin DCs was induced by GM-CSF and/or IL-4, we
administered IL-4, GM-CSF, or the combination intradermally
and analyzed DC-SIGN expression. GM-CSF alone did
increase DC-SIGN expression on both CD14+ and CD1a+
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dDCs (Figure 3f). Again, CD14+ dDCs expressed higher levels
of DC-SIGN, as indicated by a higher MFI compared with
CD1a+ dDCs. Thus, intradermal vaccination of GM/4
increased the mobilization of dDCs and upregulated the
expression of DC-SIGN on CD14+ dDCs and to some extent
of CD1a+ dDCs.
LeX- and αDC-SIGN-modiﬁed liposomes target speciﬁcally to
CD14+DC-SIGN+ dDCs
Next, we investigated whether LeX-modiﬁed liposomes are
targeted to, and internalized by, DC-SIGN+ dDCs in situ. Two
days after injection of liposomes with GM/4, emigrated dDCs
were harvested, stained for HLA-DR, and liposome internali-
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Figure 1. DC-speciﬁc ICAM-3-grabbing non-integrin (DC-SIGN) speciﬁcally binds to and internalizes LewisX- and αDC-SIGN-modiﬁed liposomes.
(a) DC-SIGN binding to modiﬁed liposomes was tested using DC-SIGN-Fc molecules. Liposomes were coated to Nunc 96-well plates at indicated concentrations;
N= 4. (b) Internalization of DiD-labeled liposomes by DC-SIGN+ monocyte-derived dendritic cell (moDCs) measured by ﬂow cytometry. Data shown
depict a representative experiment; N=4. (c) Staining for C-type lectin receptors (CLRs) expressed by moDCs. Data from one representative experiment
are shown; N= 2. (d) Internalization of modiﬁed liposomes (20 nmol ml−1) by moDCs is measured in the presence of indicated neutralizing antibodies
against CLRs; N= 3, mean ± SEM, ***Po0.001.
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zation was studied. As we could not determine any liposomes
outside of the DCs after incubation at 37 °C (Supplementary
Figure S2 online) and the liposomes are partly degraded
during the two-day migration of the dDCs after targeting, we
did not investigate the crawl-out DCs using ﬂuorescent
microscopy, but analyzed the cells using ﬂow cytometry.
Modiﬁcation of liposomes with LeX or αDC-SIGN signiﬁcantly
enhanced liposome internalization by emigrated skin DCs
(Figure 4a). Moreover, co-injection of neutralizing antibodies
against DC-SIGN abrogated the internalization of LeX- and
αDC-SIGN-modiﬁed liposomes by dDCs (Figure 4a), indica-
tive of DC-SIGN-mediated internalization.
As high expression of DC-SIGN is particularly found on
CD14+ dDCs, we analyzed liposome internalization on the
CD14+ and CD1a+ dDCs separately. Consistent with the
DC-SIGN expression in human skin, highest internalization of
DC-SIGN-targeting liposomes was detected in the CD14+
dDCs (Figure 4b). In addition, 45 and 68% of the CD14+
dDCs had taken up LeX- or αDC-SIGN-modiﬁed liposomes,
respectively, compared with 28 and 51% of the CD1a+ dDCs
(Supplementary Figure S3A online). Although the percentages
of liposome+ cells were highest in the CD14+ dDC subset, the
main difference between the two dDC subsets was observed
in the amount of liposomes taken up (measured by the MFI of
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Figure 3. Intradermal injection of GM-CSF and IL-4 alters the subset balance of emigrated dendritic cells (DCs) and increases the expression of DC-speciﬁc
ICAM-3-grabbing non-integrin (DC-SIGN). IMDM, GM/4, pI:C, LPS, or R848 were intradermally injected and numbers (a) and percentages (b) of migrated
DCs were analyzed using ﬂow cytometry. (a) Cells were stained for HLA-DR and measured during 1minute of acquisition; N=4, means ± SEM, ***Po0.001.
(b) CD1a and CD14 subset distribution was analyzed on emigrated HLA-DR+ DCs; N=4, means ± SEM, *Po0.05, **Po0.01 or ***Po0.001. (c) Absolute
numbers of CD1a+ and CD14+ dermal DCs (dDCs) were measured during 120 seconds of acquisition; N=2, means ± SEM, **Po0.01 or ***Po0.001.
(d) DC-SIGN expression on migrated CD14+ and CD1a+ dDCs after intradermal injection of indicated compounds. Cells were treated with saponin to measure
total DC-SIGN levels (intracellular and surface expression). Results from one representative donor are shown; N= 3. (e) Surface expression of DC-SIGN,
depicted as relative increase compared with medium, was analyzed on HLA-DR+ dDCs; N=3, mean ± SEM, **Po0.01. (f) Surface DC-SIGN expression
on migrated HLA-DR+ CD14+ and CD1a+ dDCs; N=3, mean ± SEM.
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Figure 2. DC-speciﬁc ICAM-3-grabbing non-integrin (DC-SIGN) is mainly
expressed by human CD14+ dermal dendritic cells (DCs). Expression of
DC-SIGN was analyzed on highly puriﬁed, FACS-sorted DC subsets present
in the human skin using real-time PCR analyses; N=3, mean ± SEM is
depicted. To ensure sufﬁciently high cell numbers, cells from at least four
individual skin donors were pooled for each DC subset.
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1,1′-Dioctadecyl-3,3,3′, 3′-Tetramethylindodicarbocyanine
(DiD)). The MFI measured on the C14+ dDCs after
internalization of LeX- or αDC-SIGN-modiﬁed liposomes
was 363 and 487, respectively, whereas the MFI measured
on the CD1a+ dDCs after internalization of LeX- or αDC-
SIGN-modiﬁed liposomes was 101 and 124, respectively
(Figure 4B). Again, neutralizing antibodies against DC-SIGN
decreased the internalization of modiﬁed liposomes
(Figure 4b).
In situ skin targeting of DC-SIGN using LeX-modiﬁed
liposomes enhances antigen presentation to CD8+ T cells by
CD14+ dDCs
Liposomal internalization via DC-SIGN may facilitate antigen
presentation to CD8+ T cells, as DC-SIGN can route
antigen to MHC-I loading compartments (Unger et al.,
2012; Garcia-Vallejo et al., 2013). Therefore, LeX-modiﬁed
liposomes containing a 15-aa-long melanoma antigen recog-
nized by T cells-1 (MART-1) peptide or a 9-aa-long Gp100
peptide were generated and injected intradermally in the
presence of GM/4. As we did not observe a difference
between the LeX- and αDC-SIGN-modiﬁed liposomes in the
antigen-presentation assays after internalization by moDCs
(Supplementary Figure S4 online), we focused on the
comparison between unmodiﬁed and LeX-modiﬁed liposomes
in experiments using human skin. Migratory DCs were
tested in antigen-presentation assays using a CD8+ T-cell
clone speciﬁc for MART-126-35(27L) or Gp100280-288. Indeed,
enhanced dose-dependent antigen presentation of the
MART-1 peptide to the CD8+ T cells was observed when
the liposomes were coated with LeX and targeted to
DC-SIGN+ dDCs, as measured by signiﬁcantly increased
production of IFN-γ (Figure 5a).
As we observed the highest internalization of the liposomes
in the CD14+ dDCs (Figure 4b) and this subset has been
described to lack the potential to cross-present antigens
(Klechevsky et al., 2008; McGovern et al., 2014), we
determined which dermal DC subpopulation contributed to
the observed effects on antigen presentation. Using magnetic-
activated cell sorting (MACS) isolation, we separated migrated
CD14+ dDCs from the CD1a+ dDCs and incubated the DC
subsets with Gp100 peptide–containing liposomes and GM/4,
after which dDCs were cocultured with Gp100-speciﬁc CD8+
T cells. MACS isolation resulted in an enrichment of separated
CD1a+ and CD14+ dDCs (Supplementary Figure S5 online).
We also analyzed CCR7 expression on the puriﬁed subsets
(Supplementary Figure S6 online). Highest expression of
CCR7 was found on the CD1a+ dDCs, which is in line with
previously reported data (McGovern et al., 2014). However,
the CD14+ dDCs did also express CCR7. With regard to CD8+
T-cell activation, Gp100-speciﬁc CD8+ T-cell reactivity was
enhanced upon coculture with DC-SIGN-targeted CD14+
dDCs but not with similarly targeted CD1a+ dDCs, providing
evidence that primarily the CD14+ dDCs are capable of
inducing CD8+ T-cell activation after antigen internalization
through DC-SIGN (Figure 5b). To exclude the possibility of an
intrinsic difference in antigen-presenting capacity between
the DC subsets, we loaded the CD14+ and CD1a+ dDCs with
the 9-aa-long Gp100 peptide, which can directly bind the
MHC-I, and co-cultured the pulsed cells with the Gp100-
speciﬁc T-cell clone. We could not observe a difference
between the two subsets in their capacity to activate the CD8+
T cells, showing that both dDC subsets were equally potent to
present antigens in MHC-I (Supplementary Figure S7 online).
Consequently, the differences in the capacity to induce CD8+
T-cell responses between the CD14+ and CD1a+ dDCs after
liposomal internalization are likely caused by the targeting
through DC-SIGN.
DISCUSSION
Here we demonstrate that LeX-modiﬁed liposomes target
antigens to DC-SIGN-expressing DCs within the human skin.
Moreover, simultaneous administration of GM/4 enhanced
the DC-SIGN expression, facilitating a DC-SIGN-mediated
internalization of LeX-modiﬁed liposomes preferentially by
CD14+ dDCs and subsequent antigen presentation to, and
activation of, CD8+ T cells.
Using the human skin explant model, we were able to
assess the internalization and fate of antigen-encapsulated
liposomes in situ. This model simulates the migration of DCs
toward the draining lymph nodes, which is the location at
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which naive antigen-speciﬁc T cells will be primed and
activated. Lymph node migration is directed by CCL19 and
CCL21 signaling through CCR7. Recently, it was shown that
CD14+ dDCs did not express CCR7, even upon stimulation
with LPS, IL-1β, and TNF-α. However, spontaneous migration
of the CD14+ dDCs from the skin was observed, suggesting
that CD14+ migratory dDCs exited the skin without entering
the lymphatics (McGovern et al., 2014). Here, we have
demonstrated that CD14+ dDCs do also express CCR7 after
spontaneous migration, indicating that these cells might
migrate to draining lymph nodes. Deﬁnitive prove showing
the capacity of CD14+ dDCs to migrate to the lymph nodes
cannot be tested in the human skin explant model and is a
topic that still needs to addressed. In addition, antigen-loaded
and matured skin-resident dDCs could also add to the
antitumor responses induced by the vaccine by providing
local antigen-speciﬁc signals that stimulate effector T cells,
especially at an immunosuppressive tumor site.
Both LeX- and the αDC-SIGN-modiﬁed liposomes were
taken up by the DC-SIGN+ dDCs to a signiﬁcantly higher
extent as compared with nontargeted liposomes. In addition,
similar CD8+ T-cell responses were observed when moDCs
were targeted with LeX- or αDC-SIGN-modiﬁed liposomes.
The use of natural ligands to target DC-SIGN in vivo is
preferred over the use of DC-SIGN-speciﬁc antibodies, as
even humanized antibodies might induce adverse immuno-
genic effects that obstruct the induction of anti-tumor
responses.
Within the human skin, DC-SIGN is predominantly
expressed by the CD14+ dDCs. We have shown that the
targeting of DC-SIGN+ dDCs under inﬂammatory conditions
using GM/4 resulted in signiﬁcantly enhanced antigen cross-
presentation to CD8+ T cells primarily by the CD14+ dDCs. In
particular, the activation of antigen-speciﬁc CD8+ T cells by
the CD14+ dDCs after DC-SIGN-mediated internalization of
antigen is an important ﬁnding, as those cells have previously
been described as poor activators of CD8+ T cells (Klechevsky
et al., 2008; Haniffa et al., 2012; Garcia-Vallejo et al., 2013).
However, we clearly show here that MACS-sorted CD14+
dDCs induced higher activation of antigen-speciﬁc effector
CD8+ T cells than CD1a+ dDCs, providing evidence that
CD14+ dDCs can present antigens efﬁciently after DC-SIGN-
mediated internalization.
The apparent discrepancy of our observation concerning
the potential of CD14+ dDCs to induce CD8+ T-cell responses
to those of others may be dependent on the method to induce
these responses. In our study, we have analyzed the capacity
of DCs to present antigens that were speciﬁcally internalized
via DC-SIGN. Others have contributed the weak CD8+ T-cell
stimulatory potential of the CD14+ dDCs based on their
capacity to cross-present soluble peptides, apoptotic cells, or
untargeted antigens (Haniffa et al., 2012; Segura et al., 2012).
It is possible that the DC-SIGN-mediated uptake of antigen
favors efﬁcient antigen routing to MHC-I processing and
loading compartments. DC-SIGN targeting thereby overrules
the poor cross-presenting potential of untargeted antigens by
CD14+ dDCs by affecting the intracellular antigen routing.
This is supported by data of our own group and others
(Tacken et al., 2005; Singh et al., 2009; Unger et al., 2012), in
which targeting of antigen to human DC-SIGN was ~ 100-fold
more efﬁcient in inducing T-cell responses than soluble
antigens.
Another possible explanation may be the intradermal
injection of GM/4. We show that GM/4 resulted in an
increased expression of DC-SIGN on both the migrated
CD1a+ and CD14+ dDC subsets, although the levels were
lower on the CD1a+ dDCs (Figure 3f). It is currently unknown
whether GM/4 can induce higher expression of DC-SIGN on
DC subsets already positive for DC-SIGN or whether it may
induce de novo expression on cells present in the intact skin
microenvironment. From in vitro studies using blood mono-
cytes, it is known that GM-CSF and IL-4 induce the
differentiation from DC-SIGNnegCD14+ monocytes to
CD1a+ moDCs with a high expression of DC-SIGN (Seager
et al., 2004). Intradermal administration of GM/4 to the skin
not only alters the expression of DC-SIGN, it also resulted in
the increased migration of the phenotypically more mature
CD1a+ dDCs (de Gruijl et al., 2006).
The speciﬁc targeting of DC-SIGN+ dDCs using glyco-
sylated liposomes eliminated the BDCA3+ dDC subset from
our analyses, as it has been described that these cells do not
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Figure 5. Intradermal targeting of LewisX (LeX)-modiﬁed liposomes results in
enhanced CD8+ T-cell reactivity. (a) HLA-A2+ skin was injected intradermally
with melanoma antigen recognized by T cells-1 (MART-1)-containing
liposomes resuspended in medium + GM/4. Emigrated DCs were harvested
after 2 days and cocultured with an HLA-A2-restricted, MART-1-speciﬁc CD8+
T clone at a ratio of 1:5. After 24 hours, IFN-γ was measured using ELISA;
n= 3, mean ± SEM, *Po0.05 and **Po0.01, using a two-way analysis of
variance (ANOVA). (b) MACS-sorted CD14+ and CD1a+ dDCs were allowed
to internalize GP100-containing liposomes and cocultured with an HLA-A2-
resricted, GP100-speciﬁc CD8+ T clone at a ratio of 1:5. After 24 hours, IFN-γ
was analyzed using ELISA; N= 3, mean ± SEM, **Po0.01 as measured
by a two-way ANOVA.
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express DC-SIGN (Chu et al., 2012). Although the
CD14-BDCA3+ DCs has been described as superior antigen
cross-presenting cells, they represent a minor population in
the skin, which makes them less suitable for targeted
immunotherapies (Haniffa et al., 2012). In addition, antigen
delivery to early endosomes through internalization via CD40
or CD11c eliminated the superior capacity of human blood
BDCA3+ DCs, resulting in a similar efﬁciency at cross-
presentation as the BDCA1+ DCs, which demonstrates
the importance of the route of antigen internalization with
regard to cross-presentation (Cohn et al., 2013). The results
presented here are in line with these ﬁndings, as we have
demonstrated that antigen internalization through DC-SIGN
allowed the CD14+ dDCs to present antigens in MHC-I and to
activate CD8+ T cells.
In conclusion, conjugation of LeX or αDC-SIGN antibodies
to liposomes facilitated in situ targeting of DC-SIGN+ DCs
after intradermal vaccination, resulting in the efﬁcient delivery
of the liposomal cargo to DC-SIGN+ DCs. Furthermore, DC-
SIGN-mediated internalization of LeX-modiﬁed liposomes
resulted in enhanced antigen presentation by GM/4-stimu-
lated dDCs and subsequently increased antigen-speciﬁc
CD8+ T-cell responses, mainly through CD14+ dDCs. There-
fore, the combined administration of glycoliposomes with
GM/4 as adjuvant represents an efﬁcient system to speciﬁcally
deliver antigens to DC subsets for the induction of CD8 T-cell
responses, and it should be considered a promising strategy
for the development of targeted antitumor immunotherapy.
MATERIALS AND METHODS
DC isolation from human skin explants
LCs and CD14+ and CD1a+ dDCs were isolated from human skin
derived from abdominal resections from healthy donors (Bergman
Clinics, Bilthoven, The Netherlands) within 24 hours after plastic
surgery. Material was obtained with informed consent (information
leaﬂet for use of 'left-over' material), which was approved by the
Medical Ethical Committee of Vumc. Skin was incubated with dispase
(Roche, Basel, Switzerland) for 16 hours at 4 °C, followed by the
separation of epidermal and dermal sheets using tweezers. Epidermal
sheets were cut in pieces and incubated for 30min at 37 °C in PBS
containing trypsin and DNase, after which the cells were run over a
100-μm cell strainer to obtain a single-cell suspension. LCs are
puriﬁed using a Ficoll gradient, resulting in ~ 90% pure LCs. To isolate
dDCs, dermal sheets were cut in small pieces and incubated in
collagenase A, dispase, and DNase for 2 hours at 37 °C. A single-cell
suspension was obtained by putting the suspension over a 100-μm
cell strainer. Where indicated, migrated dDCs and LCs were MACS-
sorted using CD1a and CD14 microbeads (MACS, Miltenyi Biotec,
Leiden, The Netherlands) or DC subsets were FACS-sorted using a
MoFlo cell sorter (Beckman Coulter, Woerden, The Netherlands) and
ﬂuorescent antibodies directed against HLA-DR, CD1a, and CD14.
Intradermal injection and culture of skin biopsies
Liposomes were diluted in serum-free medium (IMDM) and injected
intradermally, as described previously (Fehres et al., 2014). Biopsies
were taken after injection using a 6-mm biopsy punch (Microtek,
Zutphen, The Netherlands) and cultured in a 48-well plate contain-
ing 1ml of IMDM supplemented with 10% FCS, 10 μgml− 1
gentamycin, penicillin, and L-glutamine for 48 hours, at 37 °C and
5% CO2. In each experiment, 10–15 biopsies were taken per
condition. After 48 hours of culture, the biopsies were discarded and
emigrated DCs were harvested and used for experiments.
Phenotypic analysis of crawl-out cells
Analysis of emigrated cells was performed by ﬂow cytometry, as
previously described (Fehres et al., 2014). Fluochrome-conjugated
mAbs used were speciﬁc for CD1a, CD14, CD70, CD86, DC-SIGN,
HLA-DR (BD, San Jose, CA), HLA-ABC (ImmunoTools, Friesoythe,
Germany), CD83 (Beckman Coulter Immunotech, Prague, Czech
Republic), CCR7 (R&D Systems), or isotype-matched control mAbs
(BD). For the intracellular DC-SIGN staining, the cells were treated
with 0.1% saponin for 30minutes at RT, washed, and consequently
stained with DC-SIGN, CD1a, and CD14.
Real-Time PCR
FACS-sorted CD14+ dDCs, CD1a+ dDCs, and LCs were pooled from
at least four human skin donors to obtain high enough numbers for
analysis. Pooled cells were lysed and mRNA was isolated using an
mRNA Capture kit (Roche). cDNA was synthesized using the Reverse
Transcription System kit (Promega, Madison, WI) according to the
manufacturer’s guidelines. Oligonucleotides were designed using the
Primer Express 2.0 software (Life Technologies Europe, Bleiswijk, The
Netherlands) and synthesized by Invitrogen Life Technologies
(Invitrogen, Carlsbad, CA). Real-Time PCR analysis was performed
as previously described using the SYBR Green method in an ABI
7900HT sequence detection system (Applied Biosystems) (van Vliet
et al., 2006). GAPDH was used as an endogenous reference gene.
Liposome preparation
Liposomes were prepared as previously described (Joshi et al., 2011).
The MART-121-35 or Gp100280-288 peptides were encapsulated in the
liposomes, as previously described (Unger et al., 2012). Peptides
were produced by solid-phase peptide synthesis using Fmoc double-
coupling chemistry with a Symphony peptide synthesizer (Protein
Tecnologies, Tucson, AZ).
LewisX (Elicityl, Crolles, France) or anti-DC-SIGN antibody
coupling to the liposomes was done using thiol-maleimide chemistry.
To this end, a thiol group was incorporated to the glycans through
derivatization of the glycans with cysteamine (Sigma-Aldrich,
St Louis, MO) and the antibodies with N-succinimidyl S-acetylacetate
(Thermo Scientiﬁc, Waltham, MA). In brief, lyophilized glycans were
dissolved in dimethyl sulfoxide/acetic acid (8:2), and to this solution
10 equivalents (eq.) of cysteamine was added. After reacting at 65 °C
for 20minutes, 20 eq. of 2-picoline-borane (Sigma-Aldrich) was
added and the mixture was stirred for 2 hours at 65 °C, followed by
puriﬁcation by normal-phase HPLC on a Zorbax-NH2 prep column
(Agilent Technologies, Santa Clara, CA; elution water/acetonitrile,
gradient 85 to 15% of acetonitrile in 30minutes). After lyophilization
of the collected fractions, the resulting dry powder was dissolved in
water and treated with 20 eq. of tris(2-carboxyethyl)phosphine
(TCEP, Sigma-Aldrich). After 1 hour, the thio-glycan solution was
puriﬁed using disposable sephadex G10 columns equilibrated with
50mM ammonium formate (Sigma-Aldrich). Glycan derivatization
was conﬁrmed by ESI-MS (Thermo Finnigan LCQ-Deca XP Iontrap
mass spectrometer in positive mode using a nanospray capillary
needle). Antibodies were dissolved in hepes buffer, and 8 eq. of N-
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succinimidyl S-acetylacetate dissolved in a minimum amount of
dimethyl formamide was added. After 45min at room temperature,
the protein was washed three times over Vivaspin ﬁlters (10-kDa
cutoff, Sartorius, Goettingen, Germany) and then the acetyl group of
N-succinimidyl S-acetylacetate was removed by reaction with a 1:10
solution of hydroxylamine (Sigma-Aldrich) for 1 h. Subsequently, the
yielded thio-glycans or thio-antibodies were coupled to the
liposomes through a thiol-ene reaction with maleimide groups of
the 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-
maleimidophenyl) butyramide] lipid. 0.1% of the ﬂuorescent
lipophilic dye 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindodicarbo-
cyanine, 4-Chlorobenzenesulfonate Salt (DiD; Invitrogen) was added
to the liposome preparation to allow visualization after uptake by
cells using ﬂow cytometry.
Detection of glycans using ELISA
The conjugation of LeX to the liposomes was conﬁrmed by ELISA
using anti-LeX antibodies (Calbiochem, Damstadt, Germany), and
correct orientation of the glycans was assessed using DC-SIGN-Fc
molecules, as previously described (Unger et al., 2012). Brieﬂy,
liposomes were coated onto NUNC maxisorb plates (Roskilde,
Denmark) and incubated overnight at 4 °C. Plates were blocked with
1% BSA in PBS to avoid nonspeciﬁc binding. After extensive
washing, the liposomes were incubated with anti-LeX antibodies or
DC-SIGN-Fc for 1.5 hours at RT. Binding was detected using a
peroxidase-labeled F(ab′)2 goat anti-mouse IgG/Fcγ-speciﬁc anti-
body or an F(ab′)2 goat anti-human IgG/Fcγ-speciﬁc antibody,
respectively. The reaction was developed and optical density was
measured at 450 nm. As a positive control, LeX attached to
polyacrylamide (PAA) (Lectinity, Moscow, Russia) was used.
Liposome internalization by human moDCs
Human immature moDCs were generated and cultured, as previously
described (Unger et al., 2012). Liposomal uptake was analyzed by
FACS following 3 hours of incubation at 37 °C. When indicated,
20 μgml−1 neutralizing antibodies against DC-SIGN (Geijtenbeek
et al., 2000), mannose receptor (clone 19.3, BD Biosciences),
Macrophage Galactose-type Lectin (clone 125A10.03, Dendritics,
Lyon, France), Dendritic Cell ImmunoReceptor (clone 111F8.o4,
Dendritics), or langerin (de Witte et al., 2007) was added.
Liposome internalization via DC-SIGN by human skin
DC subsets
Liposomes were diluted in serum-free medium (IMDM) and injected
intradermally, as described previously (Fehres et al., 2014). When
indicated, 0.4 μg of neutralizing αDC-SIGN antibody (AZN-D1) was
co-injected per biopsy. Biopsies were taken after injection using a 6-
mm biopsy punch (Microtek) and cultured in a 48-well plate
containing 1ml of IMDM supplemented with 10% FCS, 10 μgml− 1
gentamycin, penicillin, and L-glutamine for 48 hours at 37 °C and 5%
CO2. After 48 hours of culture, the biopsies were discarded,
emigrated DCs were harvested, and DC-SIGN-mediated internaliza-
tion of DiD+ liposomes was measured using ﬂow cytometry.
Antigen presentation to human MART-1-speciﬁc or
GP100-speciﬁc CD8+ T-cell clone
An HLA-A2-restricted CD8+ T-cell clone speciﬁc for MART-126-35
was generated and cultured as described previously (Hooijberg et al.,
2000), as well as the GP100-speciﬁc CD8+ T-cell clone (Schaft et al.,
2003). Indicated concentrations of liposomes resuspended in
medium containing GM/4 were intradermally injected in the
human skin in the presence or absence of 20 μg ml−1 neutralizing
antibody against DC-SIGN (AZN-D1). After 2 days, emigrated
HLA-A2+ skin cells were harvested and 2× 104 cells/well were
seeded in a 96-well round-bottom plate. After extensive washing,
MART-1-speciﬁc or GP100-speciﬁc CD8+ T cells (105/well) were
added. After 24 hours, supernatants were taken and IFN-γ levels were
measured by sandwich ELISA using speciﬁc antibody pairs from
Biosource (San Diego, CA).
Statistical analysis
Results were analyzed using a one-way ANOVA followed by
Bonferrroni Multiple Comparison test. When stated, the two-way
ANOVA was performed using GraphPad Prism software (GraphPad
Software, San Diego, CA). Results were considered to be signiﬁcantly
different when Po0.05, *Po0.05, **Po0.01, ***Po0.001.
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